Lexeo Therapeutics, Inc. Common Stock (LXEO) - Net Assets
Based on the latest financial reports, Lexeo Therapeutics, Inc. Common Stock (LXEO) has net assets worth $231.50 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($250.36 Million) and total liabilities ($18.86 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Lexeo Therapeutics, Inc. Common Stock total assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $231.50 Million |
| % of Total Assets | 92.47% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 54.1 |
Lexeo Therapeutics, Inc. Common Stock - Net Assets Trend (2020–2025)
This chart illustrates how Lexeo Therapeutics, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Check tangible equity quality of Lexeo Therapeutics, Inc. Common Stock to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Lexeo Therapeutics, Inc. Common Stock (2020–2025)
The table below shows the annual net assets of Lexeo Therapeutics, Inc. Common Stock from 2020 to 2025. For live valuation and market cap data, see Lexeo Therapeutics, Inc. Common Stock (LXEO) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $246.67 Million | +111.11% |
| 2024-12-31 | $116.84 Million | +2.91% |
| 2023-12-31 | $113.53 Million | +200.51% |
| 2022-12-31 | $-112.95 Million | -103.15% |
| 2021-12-31 | $-55.60 Million | -904.29% |
| 2020-12-31 | $-5.54 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lexeo Therapeutics, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 37458617500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $7.00K | 0.00% |
| Other Comprehensive Income | $188.00K | 0.08% |
| Other Components | $626.61 Million | 254.03% |
| Total Equity | $246.67 Million | 100.00% |
Lexeo Therapeutics, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Lexeo Therapeutics, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Carindale Property Trust
AU:CDP
|
$324.32 Million |
|
Advanced Nano Products Co. Ltd
KQ:121600
|
$324.39 Million |
|
Perpetual Equity Investment Company Ltd
AU:PIC
|
$324.39 Million |
|
Jumbo Interactive Ltd
AU:JIN
|
$324.42 Million |
|
Yunnan Metropolitan Real Estate Development Co Ltd
SHG:600239
|
$324.25 Million |
|
Panora Gayrimenkul Yatirim Ortakligi AS
IS:PAGYO
|
$324.24 Million |
|
Thinkingdom Media Group Ltd
SHG:603096
|
$324.10 Million |
|
TechTarget, Inc. Common Stock
NASDAQ:TTGT
|
$323.99 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lexeo Therapeutics, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 116,842,000 to 246,669,000, a change of 129,827,000 (111.1%).
- Net loss of 99,961,000 reduced equity.
- Share repurchases of 79,999,000 reduced equity.
- New share issuances of 234,019,000 increased equity.
- Other comprehensive income increased equity by 291,000.
- Other factors increased equity by 75,477,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-99.96 Million | -40.52% |
| Share Repurchases | $80.00 Million | -32.43% |
| Share Issuances | $234.02 Million | +94.87% |
| Other Comprehensive Income | $291.00K | +0.12% |
| Other Changes | $75.48 Million | +30.6% |
| Total Change | $- | 111.11% |
Book Value vs Market Value Analysis
This analysis compares Lexeo Therapeutics, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.90x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-0.22 | $4.13 | x |
| 2021-12-31 | $-2.21 | $4.13 | x |
| 2022-12-31 | $-4.49 | $4.13 | x |
| 2023-12-31 | $4.26 | $4.13 | x |
| 2024-12-31 | $3.68 | $4.13 | x |
| 2025-12-31 | $4.60 | $4.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lexeo Therapeutics, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -40.52%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (-40.52%) is below the historical average (-30.53%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | -993.83% | 0.02x | 0.00x | $-4.60 Million |
| 2021 | 0.00% | -3055.04% | 0.01x | 0.00x | $-45.06 Million |
| 2022 | 0.00% | -9063.76% | 0.01x | 0.00x | $-47.98 Million |
| 2023 | -58.48% | 0.00% | 0.00x | 1.23x | $-77.75 Million |
| 2024 | -84.16% | 0.00% | 0.00x | 1.26x | $-110.02 Million |
| 2025 | -40.52% | 0.00% | 0.00x | 1.09x | $-124.63 Million |
Industry Comparison
This section compares Lexeo Therapeutics, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $128,838,508
- Average return on equity (ROE) among peers: -63.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lexeo Therapeutics, Inc. Common Stock (LXEO) | $231.50 Million | 0.00% | 0.08x | $324.29 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $143.70 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $9.08 Million | -66.39% | 1.81x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $-18.49 Million | 0.00% | 0.00x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $-2.01 Million | 0.00% | 0.00x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $10.89 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-22.51 Million | 0.00% | 0.00x | $3.66 Billion |
About Lexeo Therapeutics, Inc. Common Stock
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a… Read more